A new drug candidate targeting E. coli in the gut is in phase 1 clinical trials. According to the scientists, it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections.
Researchers have developed a DNA enzyme that can distinguish between two RNA strands inside a cell and cut the disease-associated strand while leaving the healthy strand intact. This breakthrough 'gene silencing' technology could revolutionize the development of DNAzymes for treating cancer, infectious diseases and neurological disorders.
